Notable companies
The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Intra-Cellular Therapies (NASDAQ:ITCI), Sarepta Therapeutics (NASDAQ:SRPT), BioCryst Pharmaceuticals (NASDAQ:BCRX).
Industry description
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index.
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
Market Cap
The average market capitalization across the Virtus LifeSci Biotech Products ETF ETF is 14.56B. The market cap for tickers in the group ranges from 51.4M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is BLUE at 51.4M.
High and low price notable news
The average weekly price growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was 41%. For the same ETF, the average monthly price growth was 55%, and the average quarterly price growth was 81%. BLUE experienced the highest price growth at 36%, while MRNA experienced the biggest fall at -20%.
Volume
The average weekly volume growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was 78%. For the same stocks of the ETF, the average monthly volume growth was 39% and the average quarterly volume growth was 130%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 64
P/E Growth Rating: 73
Price Growth Rating: 57
SMR Rating: 81
Profit Risk Rating: 75
Seasonality Score: -2 (-100 ... +100)